Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
Site Search
The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
The Foundation’s award will support preclinical studies of a potential phage therapy to treat resistant Pseudomonas infections.
More than 160 people with CF and their loved ones from across the country advocated for a more robust antibiotics pipeline during the CF Foundation's virtual March on the Hill.
The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.
More than 60 teens from across the country — almost half of whom live with cystic fibrosis — advocated for support of the PASTEUR Act.
Melanie Lawrence, an adult with cystic fibrosis, was selected to testify before a Senate Health, Education, Labor and Pensions subcommittee regarding the impact of antimicrobial resistance on patients who face heightened risk of infections, like those with CF.
To date, the CF Foundation has funded more than $1 million to programs created by and for the CF community.